FIELD: medicine; pharmaceuticals.
SUBSTANCE: invention relates to the use of butylphthalide or its optical isomer, deuterated product, metabolite, decyclization product or decyclization product salt in the manufacture of a medicinal product for the prevention, relief or treatment of drug-induced peripheral neuropathy.
EFFECT: use of the invention makes it possible to effectively treat drug-induced peripheral neuropathy.
14 cl, 16 dwg, 22 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| THERAPEUTIC OR PREVENTIVE MEDICINE AGAINST PERIPHERAL NEUROPATHIES | 2018 |
|
RU2770307C2 |
| APPLICATION OF L-BUTYLFTALID FOR PREPARATION OF MEDICATION FOR CEREBRAL INFARCTION PREVENTION AND TREATMENT | 2004 |
|
RU2336870C2 |
| COMPOSITIONS AND METHODS FOR TREATING DISEASE | 2007 |
|
RU2482877C2 |
| NEW COMPOSITION FOR TREATING SIDE EFFECTS OF ANTI-CANCER THERAPY | 2008 |
|
RU2485956C2 |
| PHARMACEUTICAL COMBINATION CONTAINING TNO155 AND RIBOCICLIB | 2020 |
|
RU2813111C2 |
| COMPOUNDS FOR TREATING PERIPHERAL NEUROPATHIES | 2009 |
|
RU2523281C2 |
| AGENT FOR PROPHYLACTIC AND/OR THERAPEUTIC TREATMENT OF PERIPHERAL NEUROPATHIC PAIN CAUSED BY ANTICANCER AGENT | 2013 |
|
RU2595857C2 |
| DOSAGE REGIMEN FOR AN ALPHA-ISOFORM SELECTIVE PHOSPHATIDYLINOSITOL 3-KINASE INHIBITOR | 2014 |
|
RU2680246C1 |
| NEW SYNERGETIC EFFECTS | 2009 |
|
RU2471499C2 |
| SYNERGIC COMBINATION OF PROTEASOME INHIBITOR AND VITAMIN K FOR INHIBITION OF GROWTH AND PROLIFERATION OF TUMOUR CELLS, PHARMACEUTICAL COMPOSITION AND THEREOF-BASED ANTI-TUMOUR MEDICATION | 2013 |
|
RU2563986C2 |
